BofA raised the firm’s price target on Mineralys Therapeutics (MLYS) to $46 from $43 and keeps a Buy rating on the shares after the company reported Q3 results and guided for a cash runway into 2027. A “major potential catalyst” would be Mineralys finding a commercialization and development partner, which the firm views as “necessary to maximize value,” the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS: